Inhibin is an antagonist of bone morphogenetic protein signaling.
about
Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesisRepulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4Identification of receptors and signaling pathways for orphan bone morphogenetic protein/growth differentiation factor ligands based on genomic analysesHemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogeninRegulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and InhibinIncreased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndromeMuscle regeneration in dystrophin-deficient mdx mice studied by gene expression profilingDisordered follicle developmentHeart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryosDifferential expression of TGFBR3 (betaglycan) in mouse ovary and testis during gonadogenesisRepulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptorBetaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells.Roles for the type III TGF-beta receptor in human cancerRoles for transforming growth factor beta superfamily proteins in early folliculogenesis.Bone turnover across the menopause transition : The role of gonadal inhibins.Betaglycan (TβRIII) is expressed in the thymus and regulates T cell development by protecting thymocytes from apoptosis.The Local Control of the Pituitary by Activin Signaling and Modulation.Inhibin removes the inhibitory effects of activin on steroid enzyme expression and androgen production by normal ovarian thecal cellsGDF-5 can act as a context-dependent BMP-2 antagonist.Inhibin α-subunit N terminus interacts with activin type IB receptor to disrupt activin signalingMolecular recognition in bone morphogenetic protein (BMP)/receptor interaction.Cell-type specific modulation of pituitary cells by activin, inhibin and follistatin.The role of proteins of the transforming growth factor-beta superfamily in the intraovarian regulation of follicular development.The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta/bone morphogenic protein signalling.A soluble activin type IIA receptor induces bone formation and improves skeletal integrity.Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancerEndogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes.The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor.Inhibin and premature ovarian failure.Diethylstilbestrol induces vaginal adenosis by disrupting SMAD/RUNX1-mediated cell fate decision in the Müllerian duct epithelium.BMP signaling in vascular development and disease.Activin receptor antagonists for cancer-related anemia and bone disease.Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling.Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions.Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system.
P2860
Q24296422-60964A02-1C5D-47E3-ADBD-19913A3467B6Q24304414-8BFE3666-EE00-46E8-B87C-D65F7745C204Q24310450-D7634D04-7A71-48BF-9EF0-F0806E768A44Q24321923-0C069D5F-61BB-49D7-86E3-667D25C212DEQ24633744-B2B5DF24-F295-43A6-B087-4A749EA4654EQ24654143-0386E476-49C4-4046-9879-263E9B241C0EQ24815340-F83C0086-2A2D-49ED-9C35-7B4C9517C94BQ26851230-F8C3E064-E25B-46AA-BC42-8978441A7218Q28508310-99A03243-FE76-490F-A085-61F57CE058A3Q28509393-E768AF3F-E15D-4035-9E40-25BB52C48601Q28510682-DD0DAAC7-6DD2-4D9F-8C48-0745413977B7Q33636203-A0420845-B6E3-458A-A1BA-6879EAAE01FAQ33642461-B2D62EAD-ACA1-40E1-9F3E-02F56A01C736Q33872593-58BF3608-B2AC-4D98-9611-02F80048AD4FQ34161992-640E1F29-4232-499A-B44B-B467ECC1834FQ34241748-FE96458B-87B8-415C-8E73-22BA564AEFB7Q34406454-EA539D45-A594-45AA-B747-9537C5C141BCQ35214837-43524731-6A15-4AEB-9664-093022531D3BQ35694590-6B3582D1-D74C-4FAE-8C85-752F2D032A20Q35780863-89E746F1-FEE0-4A65-85B2-5F5E97690B48Q35868268-94B79258-66DC-44D5-A647-F639D37A0085Q35902283-BDEADFE9-5112-4730-95AE-0A52793C6304Q36007410-EA3D7424-DBDA-4C63-82A5-32EAEEA09188Q36038023-4F565E7E-3469-4FE0-B48B-DAF3E4D073F3Q36337775-EB88A358-BBEF-4BEE-876B-A47E1394F477Q36401853-BD3F3650-F154-4930-B5F9-587A86BE9918Q36657509-2A88CF97-70A4-4737-A266-8B7B7E6952A2Q36898276-B7A034A1-31F4-4255-BFA1-5E364F979237Q37225724-B4035A39-74D0-449B-8F9A-45EF7C1AAD89Q37244845-9661C5D3-9B3C-418B-B6AF-0BCA5F184528Q37281661-249666AB-26D0-440D-B29D-1EE789D30D7AQ37475741-76174FB0-F3DE-4BD6-BBAB-635C62CE3846Q37484255-DF965A5A-282C-4053-A780-EB3539310EE0Q37596762-E031F259-A15C-4782-BFD4-D7442BDB66D1Q37627391-6527420E-E7CB-4C05-9799-344C8E0215BAQ37776859-AB623430-FB04-4634-A987-7DA0D14DED95Q38057813-536E6D99-EEF6-4965-97D6-AC427B77918CQ40222107-2E2FD0B5-63F4-464B-98AB-ED5B8C14EFEDQ40290804-5B03484E-4AF8-47C9-B7B6-C5465618DE78Q40505841-2832B2CE-3F37-4CAC-B795-143D9ADB2952
P2860
Inhibin is an antagonist of bone morphogenetic protein signaling.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Inhibin is an antagonist of bone morphogenetic protein signaling.
@en
type
label
Inhibin is an antagonist of bone morphogenetic protein signaling.
@en
prefLabel
Inhibin is an antagonist of bone morphogenetic protein signaling.
@en
P2860
P356
P1476
Inhibin is an antagonist of bone morphogenetic protein signaling.
@en
P2093
Ezra Wiater
Wylie Vale
P2860
P304
P356
10.1074/JBC.M209710200
P407
P577
2002-12-18T00:00:00Z